New Clinical Academic Group in Cancer Immunotherapy - CAGci

On June 28, 2018 the new Clinical Academic Group in Cancer Immunotherapy – CAGci was launched at a Copenhagen Health Science Partners (CHSP) meeting at the Maersk Tower at the University of Copenhagen Faculty of Health and Medical Sciences in Copenhagen. 

​Foto: Simon Skipper Christiansen

​The new CAG in Cancer Immunotherapy – CAGci will promote trans-institutional and cross-disciplinary research in cancer immunotherapy and will be chaired by Professor, Chief Physician and Director of the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital Inge Marie Svane and deputy leader Professor Niels Ødum from the Department of Immunology and Microbiology at the Faculty of Health and Medical Sciences at the University of Copenhagen. The new CAG in Cancer Immunotherapy - CAGci will be comprised of eight Task Forces, which will address the key challenges in cancer immunotherapy of 1) increasing available experimental immunotherapy for all, 2) facilitate the development of more complex immunotherapies, 3) develop adequate imaging tools for treatment evaluation, 4) establish biomarkers of response, 5) define real-world patient benefit, 6) unravel mechanisms of treatment resistance, 7) establish evidence based patient focused care, and 8) improve follow-up during and after immunotherapy. Members of the new CAG in Cancer Immunotherapy – CAGci will include an additional ten clinicians and research leaders in cancer immunotherapy, hematology, pediatric cancer, clinical biochemistry and physiology, and plastic surgery from Herlev Hospital, Rigshospitalet, the University of Copenhagen, and the Danish Cancer Society. Read more about the new CAGci on the CHSP homepage: www.chsp.dk.

Redaktør